RMD ResMed (RMD) Q3 FY25 earnings call
ResMed delivered a strong Q3 FY25, marked by solid revenue growth, significant gross margin expansion, and robust free cash flow generation. The company is strategically investing in R&D, manufacturing expansion, and demand generation initiatives, including new diagnostic tools and consumer outreach, to capitalize on market opportunities and address patient backlogs. Management reaffirmed its tariff exemption status and increased its share buyback program, signaling confidence in its financial position and long-term growth strategy.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
RMD operating KPIs by quarter
| KPI | Dec 2024 Q2 FY25 | This call Mar 2025 Q3 FY25 | Mar 2026 Q3 FY26 | Jun 2026 Q4 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|
| Employees | 10KThank you to all the 10,000 ResMedians for your hard work and dedication to make our mission possible.Source: earnings call transcript | 10K+Thanks to the over 10,000 ResMedians who make that happen by delivering products and services to serve patients in over 140 countries worldwide.Source: earnings call transcript | 10K+On behalf of our ResMed Board and over 10,000 ResMedians in 140 countries, I'd like to thank Brett, who I've had the privilege to partner with for 26 years, including the last 55 quarters as a CEO and CFO team.Source: earnings call transcript | 11K+I am so impressed by the talent of the more than 11,000 ResMedians around the world and their commitment to serving patients.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.